Endothelial Progenitor Cells in Health and Disease

$160.00$256.00

Amankeldi A. Salybekov, MD, PhD (Editor) – Senior Clinical Researcher, PI at Clinical Research Center, Shonan Kamakura General Hospital, Kanagawa, Japan
Shuzo Kobayashi, MD, PhD (Editor) – Kidney Diseases and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan
Takayuki Asahara, MD, PhD (Editor) – Shonan Research Institute of Innovative Medicine, Fujisawa, Japan

Series: Cell Biology Research Progress
BISAC: MED022000
DOI: https://doi.org/10.52305/ZZUL5783

We are delighted to offer this textbook to the scientific community which covers a timely topic in the rapidly evolving discipline of vascular biology. Written primarily for a life science audience and clinicians, the fundamentals of EPCs biology and the latest characterization and definition in health and diseases are introduced, followed by explanations of the most cutting-edge cell therapy methods to cure ischemic diseases.

In Section One, endothelial cell progenitor isolation methods and biological characterization were reported. The discovery of this novel endothelial progenitor cells (EPC) concept has overturned the previous dogma which suggested that vasculogenesis could only occur during embryogenesis. In fact, both vasculogenesis and angiogenesis may potentially have a synergistic role in postnatal revascularization. Also, this chapter summarized recent advances in EPC biology such as biological function, origin, definition, and classification. Each EPC culture and isolation method is clearly defined to prevent confusion in EPC biology. Section Two focuses on EPC biological function alteration in cardiovascular diseases (CVD). Several large clinical trials have reported that the number and biological function are strongly associated with major adverse cardiovascular events. The diagnostic and prognostic potential of EPC is crucial in terms of CVD. In Section Three, biological dysfunction mechanisms of EPC and their scarcity in diabetic patients’ peripheral blood were clearly described. Preclinical studies have shown that EPC-based therapy is feasible, safe, and efficacious in multiple disease states. Subsequently, this has led to several clinical trials demonstrating the feasibility and safety profile of EPC therapy against cardiovascular ischemic diseases. In Section Four, regenerative medicine pioneers discussed EPCs translation to the clinic and cell transplantation challenges along with their solutions. Personalized stem cell-based therapy approaches employing several clinical biomarkers, disease-related genetic-trait evaluation methods, and advanced analyses with state-of-the-art computational methods such as machine learning-based prediction can increase cell therapies’ efficacy and decrease treatment costs. The last chapter in the book describes a therapeutic application of EPC-derived extracellular vesicles to cure CVD.

**Order both the printed version and the e-book together and SAVE!**

Clear

Table of Contents

Preface

Section I. EPC Biological Function and Origin

Chapter 1. Advances in Endothelial Progenitor Cell Biology
Amankeldi A. Salybekov¹’²’³ and Takayuki Asahara²
¹Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Okamoto, Kamakura, Kanagawa, Japan
²Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Okamoto, Kamakura, Japan
³Qazaq Institute of Innovative Medicine, Nur-Sultan, Kazakhstan

Section II. EPC in Cardiovascular Diseases

Chapter 2. Diagnostic and Prognostic Potential of EPCs in Cardiovascular Diseases
Mehdi Hassanpour
Shonan Research Institute of Innovative Medicine, Shonan Kamakura General Hospital, Kamakura, Japan

Chapter 3. Epidemiology of Peripheral Artery Disease
Takayasu Ohtake¹’²’³ MD, PhD, and Shuzo Kobayashi²’³ , MD, PhD
1Regenerative Medicine, Center for Cell Therapy and Regenerative Medicine
2Shonan Research Institute of Innovative Medicine
3Kidney and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan

Section III. EPC in Metabolic Diseases

Chapter 4. Endothelial Progenitors in Metabolic Diseases
Mattia Albiero¹’² and Gian Paolo Fadini¹’²
¹Department of Medicine, University of Padova, Padova, Italy
²Veneto Institute of Molecular Medicine, Experimental Diabetology Lab, Padova, Italy

Section IV. Clinical EPX Transplantation Trials

Chapter 5. Endothelial Progenitor Cell Therapy in Heart Disease – Pitfalls in Clinical Translation, Impact of Stem Cell Senescence, And Personalized Medicine by AI-Application
Gustav Steinhoff¹ and Markus Wolfien²
¹Emeritus Professor of Cardiac Surgery, Department Life, Light and Matter, University Rostock, Rostock, Germany
²University Rostock, Institute of Computer Science, Department of Systems Biology and Bioinformatics, Rostock, Germany

Chapter 6. EPC in Peripheral Arterial Diseases
Yasuyuki Fujita and Atsuhiko Kawamoto
Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan

Chapter 7. EPC in Kidney Diseases
Takayasu Ohtake¹’²’³ MD, PhD, and Shuzo Kobayashi²’³ MD, PhD
¹Regenerative Medicine, Center for Cell Therapy and Regenerative Medicine
²Shonan Research Institute of Innovative Medicine
³Kidney and Transplant Center, Shonan Kamakura General Hospital, Kamakura, Japan

Section V. EPC Derived Extracellular Vesicles

Chapter 8. Therapeutic Applications of Endothelial Progenitor Cell-Derived Extracellular Vesicles in Cardiovascular Diseases
Junjie Yang¹ and Jiacheng Sun²
¹Department of Anaesthesiology, University of Maryland School of Medicine, Baltimore, USA
²Department of Biomedical Engineering, University of Alabama at Birmingham, School of Medicine and School of Engineering, Birmingham, USA

Index